Shein Scales Back Vietnam Operations as US Trade Rules Shift 
ADNOC Gas Targets Up to $4B Profit in 2026 
Airbus Joins Air India A320 Altitude Drop Probe 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
MOUNTAIN VIEW, Calif., Feb. 20, 2018 -- Amunix Operating Inc. (Amunix), a biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapeutics, is pleased to announce that it has entered into a licensing agreement with Celgene. The agreement allows for the utilization of Amunix’s proprietary XTEN and ProTIA technology to augment ongoing discovery and development of therapeutics with the potential for improved delivery, enhanced safety, targeted delivery, and half-life attributes against specified targets selected by Celgene.
Volker Schellenberger, PhD, CEO of Amunix commented: “We are extremely pleased by the decision made by the Celgene team in selecting Amunix’s XTEN and ProTIA technologies to further enhance the development of its therapeutic drug pipeline. We look forward to future milestone achievements in the development of novel entities from the collaborative effort between our companies.” Geller Biopharm, Inc. served as Amunix’s exclusive agent for this licensing agreement.
About Amunix:
Amunix, based in Mountain View, CA, is a privately held biotechnology company with two proprietary technologies, XTEN and ProTIA. XTEN is a half-life extension technology is based on hydrophilic, unstructured, biodegradable proteins that impart a number of favorable properties upon the molecules to which they are attached. In addition to the advantages of reduced dosing frequency, XTENylation stabilizes plasma drug concentrations, which often results in increased efficacy as well as reduced side effects. Amunix has licensed this technology to numerous companies in a wide range of therapeutic areas. Two genetically fused XTENylated products have been clinically tested.
ProTIAs are bispecific molecules that bind tumor antigens and T cells. ProTIAs are administered as long-acting prodrugs that can be activated in the tumor environment by tumor-associated proteases. Amunix is developing internally a pipeline of ProTIA-based (Protease Triggered Immune Activator) immuno-oncology therapeutics, as well as offering partners access to the ProTIA technology for augmenting the safety and efficacy of their molecules. For additional information about the company, please visit www.amunix.com.
Contact:
Volker Schellenberger, Ph.D.
President and CEO
Tel: 650-889-5095
[email protected]
